Ignite Creation Date:
2024-05-05 @ 11:59 PM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01462006
Status:
COMPLETED
Last Update Posted:
2021-03-22
First Post:
2011-10-26
Brief Title:
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis IPF
Sponsor:
University of Virginia
Organization:
University of Virginia
Study Overview
Official Title:
Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Idiopathic pulmonary fibrosis IPF is an illness characterized by progressive decline in lung function and premature death from respiratory failure Fibrocytes are a novel population of bone marrow-derived circulating progenitor cells that have been shown to traffic to the lungs and contribute to fibrosis in animal models of pulmonary fibrosis and whose numbers correlate with the degree of fibrosis and with survival in human pulmonary fibrosis The investigators propose to test the hypothesis that therapy with the mTOR inhibitor sirolimus reduces the number of circulating fibrocytes in patients with IPF The investigators propose to test this hypothesis in short-term pilot trial of sirolimus in patients with IPF to determine its effect on the number and phenotype of circulating fibrocytes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL098329 | NIH | None | httpsreporternihgovquickSearchR01HL098329 |